Measure Title: Management of the axilla in breast cancer patients undergoing breast conserving surgery with a positive sentinel node biopsy

Measure Type: Process of care

National Quality Strategy Domains: Safety (sentinel node only has less patient risk than complete axillary dissection), efficiency and cost reduction (appropriateness); effectiveness

Description: Percent of Z0011 eligible breast cancer patients who do not undergo completion axillary dissection

Denominator: Number of Z0011 eligible breast cancer patients.

Numerator: Number of Z0011 eligible breast cancer patients who do not undergo completion axillary dissection

Exclusions: Patients not meeting eligibility criteria for ACOSOG Z0011: require mastectomy; have >2 positive SLN; matted nodes; gross extra-nodal disease; Tis tumor only or T3 or T4 tumor; N1mi (nodal involvement is <2mm across and/or more than 200 cells but is not larger than 2 mm); neoadjuvant therapy; lumpectomy without radiation therapy (RT); pure lobular carcinoma in situ (LCIS) without invasive cancer

Exceptions: none

Rationale: Based on a randomized trial and two recent systematic reviews, most SLN-positive patients who meet the ACOSOG Z0011 eligibility criteria do not require ALND.

Date Endorsed: February 26, 2015, Revised December 8, 2015, June 20, 2017.
